Condensed Consolidated Interim Financial Statements For the three months ended March 31, 2021 and 2020 (Unaudited)

(Expressed in thousands of Canadian dollars)

Condensed Consolidated Statements of Financial Position (Unaudited)

(Expressed in thousands of Canadian dollars)

	Notes	March 31, 2021 \$	December 31, 2020 \$
Assets			
Current assets			
Cash and cash equivalents		37,456	16,442
Accounts receivable		5,007	2,416
Inventory		1,615	1,624
Prepaid expenses and other receivables		1,094	1,125
Contract assets	4	5,521	2,518
		50,693	24,125
Property and equipment		765	821
Intangible assets		7,489	7,821
Goodwill	_	10,405	10,405
	<u>.</u>	69,352	43,172
Liabilities			
Current liabilities			
Accounts payable and accrued liabilities		13,155	8,773
Contract liabilities	4	639	1,661
Lease liability, current portion		229	225
Warranty liability, current portion	5	118	121
Promissory note	6	-	5,957
		14,141	16,737
Lease liability, non-current portion		399	461
Warranty liability, non-current portion	5	-	106
		14,540	17,304
Shareholders' Equity			
Share capital	7	60,588	31,927
Contributed surplus		1,941	1,547
Accumulated other comprehensive income		230	111
Deficit	<u>-</u>	(7,947)	(7,717)
	<u>-</u>	54,812	25,868
		69,352	43,172

Approved by the Board of Directors and authorized for issue on May 12, 2021

"Wade Nesmith"	Director	"David Blaiklock"	Director
----------------	----------	-------------------	----------

Condensed Consolidated Statements of Operations and Comprehensive Loss For the three months ended March 31, 2021 and 2020 (Unaudited)

(Expressed in thousands of Canadian dollars except number of shares and per share amounts)

	Three months ended March 31, 2021 \$	Three months ended March 31, 2020 \$
Revenue	12,205	2,930
Cost of goods sold (excluding amortization)	(8,921)	(1,642)
	3,284	1,288
Amortization	(314)	(309)
Gross profit	2,970	979
General and administration	(865)	(944)
Salaries and benefits	(1,730)	(986)
Depreciation	(76)	(71)
Research and development	(85)	(27)
Share-based payments	(175)	(22)
Operating income (loss)	39	(1,071)
Other income (expenses):		
Finance expense	(59)	(166)
Other income	209	-
Foreign exchange gain (loss)	(419)	144
Net loss	(230)	(1,093)
Other comprehensive loss Item that may be subsequently reclassified to net loss:		
Foreign currency translation adjustment	119	101
Total comprehensive loss	(111)	(992)
Basic and diluted loss per share	(0.00)	(0.01)
Weighted average numbers of shares	130,593,823	79,073,677

Condensed Consolidated Statement of Changes in Equity For the three months ended March 31, 2021 and 2020 (Unaudited)

(Expressed in thousands of Canadian dollars, except for number of common shares)

	Share capital (number of shares)	Share capital \$	Contributed surplus \$	Accumulated other comprehensive income \$	Deficit \$	Total \$
Balance, January 1, 2020	68,435,795	11,282	1,510	152	(5,246)	7,698
Share-based compensation expense	-	-	- 22	_	-	22
Warrants exercised	9,000	3	-	-	-	3
Options exercised	231,680	47		-	-	33
Shares/warrants issued	23,000,000	10,741	759	-	-	11,500
Agent options issued	-	-	235	-	-	235
Share issuance costs	-	(1,300)	(91)	-	-	(1,391)
Currency translation adjustment	-	-		101	-	101
Net loss for the period	-	-		-	(1,093)	(1,093)
Balance, March 31, 2020 Balance, January 1, 2021	91,676,475	20,773 31,927	, ,	253 111	(6,339) (7,717)	17,108 25,868
Share-based compensation expense	-	-	- 175	_	-	175
Warrants exercised	11,304,677	4,650	(501)	-	-	4,149
Options exercised	696,983	395	(109)	-	-	286
Shares issued	12,190,000	26,452		-	-	26,452
Share issuance costs	-	(2,836)) -	-	-	(2,836)
Agent warrants issued	-	-	829	-	-	829
Currency translation adjustment	-	-		119	-	119
Net loss for the period		-		-	(230)	(230)
Balance, March 31, 2021	138,873,116	60,588	3 1,941	230	(7,947)	54,812

Condensed Consolidated Interim Statements of Cash Flows For the three months ended March 31, 2021 and 2020 (Unaudited)

(Expressed in thousands of Canadian dollars)

	Three months ended March 31, 2021 \$	Three months ended March 31, 2020 \$
Cash provided by (used in)		
Operating activities		
Loss for the period	(230)	(1,093)
Adjustments for non-cash items Unrealised foreign exchange (gain) loss	419	(144)
Depreciation and amortization	390	380
Finance expense	59	166
Share-based compensation	175	22
Other income	(209)	-
	604	(669)
Other adjustments		
Changes in current assets	(2,882)	(126)
Changes in current liabilities	4,575	97
Changes in contract assets and liabilities	(4,025)	(1,479)
Interest paid on leases	(11)	(15)
Cash used in operating activities	(1,739)	(2,192)
Investing activities		
Purchase of property and equipment	(20)	(21)
Cash used in investing activities	(20)	(21)
U		· · · ·
Financing activities		
Proceeds from issuance of shares and warrants	26,452	11,500
Share issuance costs	(1,996)	(1,157)
Proceeds from options and warrants exercised	4,431	36
Payments on promissory note	(6,041)	(3,614)
Lease payments Cash generated by financing activities	(73)	(81) 6,684
Cash generated by infancing activities	22,773	0,004
Increase in cash and cash equivalents	21,014	4,471
Cash and cash equivalents – Beginning of period	16,442	2,269
Cash and cash equivalents — End of period	37,456	6,740

Notes to Condensed Consolidated Interim Financial Statements For the three months ended March 31, 2021 and 2020 (Unaudited)

(tables in thousands of Canadian dollars, except per share amounts)

1 Nature of operations

Greenlane Renewables Inc. ("Greenlane" or "the Company") was incorporated under the British Columbia Business Corporations Act on February 15, 2018. The Company's primary business is a provider of biogas upgrading systems. Its systems produce clean, renewable natural gas from organic-waste sources including landfills, wastewater treatment plants, dairy farms, and food waste, suitable for either injection into the natural gas grid or for direct use as vehicle fuel. The head office of the Company is located at 110-3605 Gilmore Way, Burnaby, BC, V5G 4X5 and its registered and records office is located at 1500-1055 West Georgia Street, Vancouver, BC, V6E 4N7.

2 Basis of presentation

These condensed consolidated interim financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) applicable to the preparation of interim financial statements, including International Accounting Standard 34 Interim Financial Reporting and should be read in conjunction with the Company's most recent annual consolidated financial statements. These condensed consolidated interim financial statements follow the same accounting policies and methods of application as the Company's most recent annual consolidated financial statements.

These condensed consolidated interim financial statements have been prepared on a historical cost basis and are presented in Canadian dollars, which is also the Company's functional currency. These condensed consolidated interim financial statements were approved and authorized for issue by the Board of Directors on May 12, 2021. Certain of the comparative period figures, including the presentation of expense categories within the Statement of Operations and geographic areas within the segmented information note, have been reclassified to conform to the current period's presentation for more relevant information.

3 Key sources of estimation uncertainty

The preparation of the condensed consolidated interim financial statements in conformity with IFRS requires the Company's management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected. The judgements made by management in applying the Company's accounting policies and key sources of estimation uncertainty are consistent with those reported in the December 31, 2020 annual audited financial statements.

Notes to Condensed Consolidated Interim Financial Statements For the three months ended March 31, 2021 and 2020 (Unaudited)

(tables in thousands of Canadian dollars, except per share amounts)

4 Contract balances

	Balance at December 31, 2020	Revenue Recognized	Progress Billings	Balance at March 31, 2021
	\$	\$	\$	\$
Contract Assets	2,518	8,964	(5,961)	5,521
Contract Liabilities	(1,661)	2,604	(1,582)	(639)
	857	11,568	(7,543)	4,882

The Company receives payments from customers based on the stage of completion of a contract. Contract assets relate to the Company's conditional right to consideration for the completed performance under the contract. Accounts receivable are recognized when the right to consideration becomes unconditional. Contract liabilities relate to stage payments that are received in advance of performance under the contract.

The revenue recognized during the quarter and the contract balances at March 31, 2021 primarily relates to seven projects.

5 Warranty liabilities

The Company provides a warranty following the sale of certain products. As a consequence, the Company has recorded a provision for future warranty claims. Warranty periods vary between products but are typically one to two years from commissioning of equipment. The provision is based on management's best estimate of future claims, taking account of historical experience and knowledge of the installations covered by the warranty. As the warranties are short-term in nature, no discounting has been assumed.

Balance, January 1, 2021	227
Charges against provision	(9)
Provision expired	(100)
Balance, March 31, 2021	118
Less: Current portion	118
Non-current portion	

\$

Notes to Condensed Consolidated Interim Financial Statements For the three months ended March 31, 2021 and 2020 (Unaudited)

(tables in thousands of Canadian dollars, except per share amounts)

6 Promissory note

The promissory note incurred interest at 7% per annum and had a maturity date of June 30, 2021. On February 12, 2021, the promissory note was repaid early, in full, including interest and principal.

	Balance \$
Balance, December 31, 2020	5,957
Interest accrual	3,937 47
Foreign exchange movement	37
Repayments	(6,041)
Balance, March 31, 2021	

7 Share capital

Common shares

At March 31, 2021, the Company had unlimited authorized common shares without par value and 138,873,116 common shares issued and outstanding (December 31, 2020 – 114,681,456).

On January 27, 2021, the Company completed a bought deal offering with TD Securities Inc. (lead underwriter, the "Underwriters") through the issuance of 12,190,000 common shares, at a price of \$2.17 per share for gross proceeds of \$26.5 million and incurred \$2.0 million in cash expenses. The Company issued compensation warrants to the Underwriters entitling them to purchase an aggregate of 731,400 common shares at a price of \$2.17 for a period of one year from closing. The fair value of the warrants issued (valued using the Black-Scholes pricing model, see below for list of assumptions) of \$0.8 million has been included in share capital as part of the share issuance costs.

Grant date	January 27, 2021
Number of warrants granted	731,400
Fair value per option	\$1.13
Risk-free rate	0.13%
Expected volatility	109%
Expected life in years	1
Expected dividend yield	-

During the three months ended March 31, 2021, 696,983 options were exercised, and the fair value of \$0.1 million was transferred from contributed surplus to share capital. In addition, 11,304,677 warrants were exercised, and the fair value of \$0.5 million was transferred from contributed surplus to share capital.

Notes to Condensed Consolidated Interim Financial Statements For the three months ended March 31, 2021 and 2020 (Unaudited)

(tables in thousands of Canadian dollars, except per share amounts)

Warrants outstanding

At March 31, 2021, the Company had 11.7 million warrants outstanding (December 31, 2020 – 22.4 million), as follows:

Warrant exercise price	\$0.26	\$0. 70	\$2.1 7	Total
Expiry	June 3, 2021	Feb 19, 2021	Jan 27, 2022	
Number of warrants, December 31, 2020	19,698,147	2,655,600	-	22,353,747
Granted	-	-	731,400	731,400
Exercised	(8,677,507)	(2,590,600)	(36,570)	(11,304,677)
Cancelled	-	(65,000)	-	(65,000)
Number of warrants, March 31, 2021	11,020,640		694,830	11,715,470
Cash proceeds from exercise	\$2,256	\$1,813	\$79	\$4,148

During the period ended March 31, 2021, a total of 11.3 million warrants were exercised for \$4.1 million (March 31, 2020: 9,000 warrants for \$2,340). The fair value associated with the warrant exercises of \$0.5 million was transferred from contributed surplus to share capital. On expiry of the \$0.70 warrants on February 19, 2021, 65,000 warrants remained unexercised and were cancelled.

Stock options

The Company has a stock option plan whereby the Company may grant stock options to eligible employees, officers, directors and consultants at an exercise price, expiry date and vesting conditions to be determined by the Board of Directors. The maximum term to expiry is 10 years from the date of grant. All options are equity settled. The stock option plan provides for the issuance of up to 10% of the issued and outstanding common shares at the date of grant.

A summary of the Company's stock options outstanding for the three months ended March 31, 2021, including options granted to agents is as follows:

Number of options	Weighted average exercise price \$
5,241,984	0.27
190,000	1.94
(696,983)	0.41
(21,667)	0.41
4,713,334	0.33
	options 5,241,984 190,000 (696,983) (21,667)

At March 31, 2021, 2,962,083 options were exercisable (December 31, 2020 – 3,604,650).

Notes to Condensed Consolidated Interim Financial Statements For the three months ended March 31, 2021 and 2020 (Unaudited)

(tables in thousands of Canadian dollars, except per share amounts)

The following table summarizes information about stock options outstanding as at March 31, 2021:

Exercise price	Number outstanding	Weighted average remaining life in years
\$0.10	675,000	7.59
\$0.20	2,761,334	3.19
\$0.39	142,000	4.41
\$0.50	720,000	4.16
\$0.74	225,000	4.57
\$1.94	190,000	4.96

There was one option grant during the period. The value of the stock options issued was estimated using the Black-Scholes option pricing model with the following assumptions:

Grant date	March 16, 2021
Number of options granted	190,000
Fair value per option	\$1.26
Risk-free rate	0.21%
Expected volatility	99.67%
Expected life in years	3.5
Expected dividend yield	-

At March 31, 2021 stock options issued represented 3.4% of issued and outstanding common share capital. The Company recognized share-based compensation cost relating to stock options of \$0.1 million during the three months ended March 31, 2021.

Restricted Share Unit Plan

Under the Company's restricted share unit plan, the Company may grant a maximum of 9,687,030 common shares of the Company to directors, officers and consultants. During the first quarter of 2021, the Company granted 130,414 restricted share units ("RSUs") to non-executive directors with vesting after one year. The weighted average fair value of \$2.31 per RSU was determined based on the Company's share price on the grant date with no adjustments for dividend yield or other terms and conditions. The Company recognized share-based compensation expense of \$0.1 million during the three months ended March 31, 2021, related to RSUs.

A total of 1,090,452 RSUs have been granted under the plan.

Notes to Condensed Consolidated Interim Financial Statements For the three months ended March 31, 2021 and 2020 (Unaudited)

(tables in thousands of Canadian dollars, except per share amounts)

8 Related party transactions

Key management includes Directors, the Chief Executive Officer (CEO) and the Chief Financial Officer (CFO), who have the authority and responsibility for the planning, directing and controlling the activities of the Company. The compensation paid to these key management personnel for the three months ended March 31, 2021 and 2020 is outlined below:

	Three months ended March 31, 2021 \$	Three months ended March 31, 2020 \$
Non-executive Directors fees (excluding share-based compensation)	76	-
Salary	156	135
Share-based compensation	114	2
<u></u>	346	137

In February 2021, the Company settled all amounts due to the former parent company of PT Biogas Holdings Limited ("PT Biogas"), relating to the acquisition of PT Biogas by the Company in June 2019, including the outstanding promissory note (\$6.0 million, Note 6) and intercompany invoices (\$0.4 million).

9 Segmented information

The Company has one operating segment, which is further broken down into two revenue streams, system sales and aftercare service.

	Three months ended March 31, 2021	Three months ended March 31, 2020
	\$	\$
System sales	11,568	2,086
Aftercare sales	637	844
	12,205	2,930

The Company operates in the Americas and Europe and generates revenue from various regions internationally, as shown below.

Notes to Condensed Consolidated Interim Financial Statements For the three months ended March 31, 2021 and 2020 (Unaudited)

(tables in thousands of Canadian dollars, except per share amounts)

	Three months ended March 31, 2021 \$	Three months ended March 31, 2020 \$
System sales revenue		
United States	10,703	891
Brazil	848	62
Canada	17	1,133
	11,568	2,086
Aftercare services revenue		
United States	28	66
Brazil	4	4
Canada	46	29
United Kingdom	353	527
Other	206	218
	637	844
Total revenue		
United States	10,731	957
Brazil	852	66
Canada	63	1,162
United Kingdom	353	527
Other	206	218
	12,205	2,930

The Company had three customers that each accounted for 10% or more of total revenue during the three months ended March 31, 2021. These customers accounted for 34%, 32% and 17% of total revenue.

10 Financial instruments

Financial assets and liabilities recorded or disclosed at fair value in the consolidated statements of financial position are categorized based on the level of judgment associated with the inputs used to measure their fair value.

The Company's financial assets and financial liabilities, are measured and/or disclosed at fair value by level within the fair value hierarchy. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's policy is to recognize transfers in and out of the fair value hierarchy levels as of the date of the event or change in circumstances that caused the transfer. There were no such transfers during the period ended March 31, 2021.

At March 31, 2021, the carrying amounts of cash and cash equivalents, accounts receivables, other receivables, accounts payable and accrued liabilities, approximate their fair value due to their short-term nature.